Pediatric Cannabis Edible Ingestions Are Rising and Need Better Clinical Guidelines

Cannabis edible products pose significant health risks to children due to inconsistent governmental regulation of manufacturing, packaging, and labeling. The variation in components and potencies causes a wide range of dose-dependent adverse events. Consumer education and harm reduction strategies are lacking, leading to increased unintentional pediatric ingestions. The review provides recommendations for screening, management, and prevention.

Clinical review providing medical and pharmacological context on cannabis edibles in the U.S., with recommendations for initial screening, management, and prevention of pediatric cannabis ingestions.

As cannabis edibles become more available and are designed to look like regular candy or baked goods, accidental pediatric exposures are rising. Children metabolize THC differently than adults, and there are no standardized protocols for managing these exposures, leaving clinicians without clear guidance.

The cannabis industry's focus on appealing product forms (gummies, chocolates, cookies) creates an inherent risk for children who cannot distinguish these from regular treats. Until packaging and child-resistance standards match those for pharmaceuticals, accidental pediatric exposures will likely continue to rise.

Narrative clinical review. Does not quantify the exact magnitude of the problem. U.S.-focused. Rapidly evolving regulatory landscape means recommendations may need frequent updating.